The ENDS 2018 Advisory Board worked together with Smithers Rapra to produce a balanced and informative programme, that covered the most important ENDS-related topics.
See below for more information about the 2018 Advisory Board members.
Biographical information to follow...
Ian is a Director of Tobacco Research at Celerion, a provider of clinical research capabilities and expertise to the tobacco and e-cigarette industry. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation. Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada. Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters which have generated over 2,200 citations.
Andrew Feilden joined Smithers Rapra as a Principal Consultant in June 2011 and was appointed Chemistry Operations Director in October 2012. He specializes in extractable and leachable testing and the selection and assessment of materials for medical and pharmaceutical applications. Andrew previously worked at AstraZeneca for 12 years, leading their extractable and leachable testing. He has been working in the field of trace analysis using hyphenated techniques such as GC-MS and LC-MS for over 12 years. Whilst at AstraZeneca he was an active member of industry working groups, the IPAC-RS container closure group and he was the co-chair of ELSIE material group. Andrew gained a degree and D.Phil from York University.
Scott is the Director of Analytical Services at Crawford Scientific where he heads up their specialist MS based laboratory, Hall Analytical, in Manchester, UK.
Hall Analytical has a long association with e-cigarette analysis and development with over 10 years experience of preforming analytical testing on the very early cigalike prototypes.
Before this he spent many years working as a professional trainer and consultant in analytical chemistry and prior to that he worked in the pharmaceutical industry in the incredibly analogous field of developing dry powder inhalers!
Scott sits on the Separation Science Committee of the Royal Society of Chemistry, of whom he is a Fellow, and on the Editorial Advisory Board of various Separation Science publications and is regular speaker at national and internal conferences.
Liam Humberstone is Technical Director at Totally Wicked Limited. His involvement with standards and regulations for e-cigarettes and e-liquid started with a notorious legal challenge, but he has since worked collaboratively with regulators at UK National, European and other International levels. His background is in design engineering and scientific research, and he has been involved in the e-cigarette industry since 2011.
A global legal and compliance industry expert Patricia I. Kovacevic’s experience comprises general counsel and chief compliance officer roles at Nicopure Labs LLC, and leading senior legal and compliance positions at, among others, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy, product development and launch. Kovacevic served on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. In the past she was a United Nations staff member, served on the U.N.’s Public-Private Partnership Commission and was also an adviser to the Council for Burley Tobacco. Kovacevic is admitted to practice in New York and before the Supreme Court of the United States. She holds a J.D. from Columbia Law School in New York and has completed the Harvard Business School “Corporate Leader” course. She is fluent in seven European languages.
Dr Dan Myers has significant expertise in the research and development of pharmaceutical and medical devices, particularly inhalation products. His work has resulted in commercially FDA-approved products.
Dan is one of the founding partners in a recent company called Reveritas Group, whose aim is to provide regulatory consulting for ENDS companies. Concurrently, Dan serves as the Principal Investigator on an NJOY Small Business Innovation Research contract with the National Institute of Drug Abuse to create a standardized electronic nicotine delivery system (ENDS) that medical scientists can use for clinical research. This work culminated in the very first Drug Master File for an ENDS submitted to FDA. As Vice President of Research & Development at NJOY, Dan led the technical project team during development of several commercially-realized products, most notably the NJOY Daily, a disposable electronic cigarette which launched commercially in September 2015 and has been extremely successful in the market.
Prior to NJOY, Dan was one of the lead scientists at Alexza Pharmaceuticals for 13 years, involved in the discovery, development, and ultimately the commercialization of a novel inhaler technology involving thermal vaporization of pure drugs. His responsibilities at Alexza included discovery and understanding of the basic science of thermal vaporization of pharmaceuticals, analytical testing of aerosols, process development of spray coating technology, management of multiple scientists and engineers within the product research & development team, serving as the technical project lead on several pipeline drug products, determining company strategy on intellectual property, and assisting with business and due diligence assessments with potential partners. At Alexza, Dan gained extensive interactions with the FDA - attending four meetings at FDA and multiple on-site audits with FDA at the Alexza manufacturing facility, co-authoring six Investigational New Drug filings and one New Drug Application which was approved by FDA and EMA. Dan’s work at Alexza garnered him the acknowledgement of the company’s first eXcellence award as employee of the year.
Dan earned a Ph.D. in chemistry (chemical physics track) from Stanford University with graduate fellowships from the National Science Foundation and the G.J. Lieberman foundation. Dan was awarded BS degrees in mathematics and chemistry (graduating with university, college, and department honors) from Carnegie Mellon University. He has published 21 peer-reviewed papers and has 16 US patents.